key: cord-0872491-cr6buc9g
authors: Ghaznavi, Habib; Shirvaliloo, Milad; Sargazi, Saman; Mohammadghasemipour, Zahra; Shams, Zinat; Hesari, Zahra; Shahraki, Omolbanin; Nazarlou, Ziba; Sheervalilou, Roghayeh; Shirvalilou, Sakine
title: SARS‐CoV‐2 and influenza viruses: Strategies to cope with coinfection and bioinformatics perspective
date: 2022-04-02
journal: Cell Biol Int
DOI: 10.1002/cbin.11800
sha: 083e7dbb14f91236dcc00def9a3c2585a63f47be
doc_id: 872491
cord_uid: cr6buc9g

Almost a century after the devastating pandemic of the Spanish flu, humankind is facing the relatively comparable global outbreak of COVID‐19. COVID‐19 is an infectious disease caused by SARS‐CoV‐2 with an unprecedented transmission pattern. In the face of the recent repercussions of COVID‐19, many have argued that the clinical experience with influenza through the last century may have tremendous implications in the containment of this newly emerged viral disease. During the last 2 years, from the emergence of COVID‐19, tremendous advances have been made in diagnosing and treating coinfections. Several approved vaccines are available now for the primary prevention of COVID‐19 and specific treatments exist to alleviate symptoms. The present review article aims to discuss the pathophysiology, diagnosis, and treatment of SARS‐CoV‐2 and influenza A virus coinfection while delivering a bioinformatics‐based insight into this subject matter.

| 1

2019-2020 influenza outbreak had resulted in tens of millions of patients in the United States before the unwelcome reign of COVID-19 started (Singer, 2020 The newly identified viral strain called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes significant morbidity and mortality as an impending consequence of acute respiratory distress syndrome (Sheervalilou et al., 2020; . This is why we now live in a distinctly different world with a redefined lifestyle (Debby & David, 2020) . In the absence of relevant information regarding the pathogenesis of SARS-CoV-2, the rational alternative was to turn to our previous experience with outbreaks such as SARS, MERS, and influenza. There were conclusive libraries of information particularly concerned with the pathogenesis of these causative agents (Debby & David, 2020; . However, the overwhelmingly high fatality rate of COVID-19 urged the scientific society to learn about this new calamity as quickly as possible (Sheervalilou, Shirvaliloo, Sargazi, Bahari, et al., 2021; .

To date, there has been officially approved specific medication for the treatment of COVID-19 as well as vaccines; hence, the need to comply with the tried-and-true methods such as self-isolation and prevention of infection. This is because developing novel therapeutic agents, or even repurposing the old ones, is a rather challenging task for clinicians. They first need to make an evident lab-based diagnosis of the disease due to the many similarities it shares with other viral infections . It is well established that the primary intervention in the case of any contagious disease is immunization of individuals against the causative agents through vaccination (Azizi & Azizi, 2020) . Several vaccines have been approved for emergency use against COVID-19 (Aruru et al., 2021) , including vaccines developed by Pfizer and BioNTech. Nevertheless, researchers are still trying to design a more effective vaccine versus the SARS-CoV-2 36. Table 1 displays various vaccine platforms utilized versus CoVs (Anderson et al., 2020; Buchholz et al., 2004; H.-W. Chen et al., 2016; Graham et al., 2018; Hashemi et al., 2021; Jimenez-Guardeño et al., 2015; Kalita et al., 2020; T. W. Kim et al., 2004; Menachery et al., 2018; Spruth et al., 2006; Takashima et al., 2011; S.-F. Wang et al., 2014; Zakhartchouk et al., 2007; Zhang et al., 2020) .

It is a pressing concern to find that many investigations focus on isolated infection with SARS-CoV-2 while overlooking instances of simultaneous infection with another pathogen or even pathogens.

This is an important issue as coinfection with several pathogens may interfere with an accurate diagnosis of COVID-19 and result in discrepancies in the therapeutic window related to either one of the infections . Before the SARS-CoV-2 outbreak, respiratory viral coinfections were reported in about 40% of patients with flu-like symptoms (Pinky & Dobrovolny, 2020) . More recently, a meta-analysis concluded that nearly 3% of patients hospitalized with the diagnosis of COVID-19 were simultaneously infected with other respiratory pathogens, with influenza A being the secondary infection in most of the cases (Lansbury et al., 2020) . As the more recent studies suggest, there has been a descending trend in the detection of coinfection in adults diagnosed with COVID-19 (Blasco et al., 2020; Nowak et al., 2020; Siordia, 2020; Xing et al., 2020) . Still, the same statement cannot be made for pediatric patients with COVID-19, as they showed a 40% coinfection rate with another pathogen along SARS-CoV-2 in several investigations . It is unclear whether coinfection with another pathogen may result in unfavorable therapeutic outcomes in patients infected with SARS-CoV-2. According to two separate investigations, SARS-CoV-2/influenza coinfection did not result in worse clinical outcomes (Ding et al., 2020 Coinfections contribute to the morbidity and mortality accompanied by influenza infection (Dunning et al., 2020) . Early data from

China showed that nearly 50% of the patients who deceased due to COVID-19 disease were also infected with the influenza virus at the time . Viral infections of the respiratory tract predispose individuals to more severe forms of COVID-19. Cases of coinfection with SARS-CoV-2 and influenza A virus have been frequently reported, bringing about certain challenges in the diagnosis and treatment of concordant infections disease (Khorramdelazad et al., 2021) . There are also other reports with more lenient results, suggesting a 10% rate of coinfection at the highest (N. Chen et al., 2020;  bound effectively to the S1 subunit of SARS-CoV-2 S protein, as well as

Oolonghomobisflavan-A that could bind and neutralize the SARS-CoV-2 main protease Bhardwaj, Singh, Sharma, et al., 2021a) . Further investigations identified three bioactive molecules from tea (epicatechin-3,5-di-O-gallate, epigallocatechin-3,5-di-O-gallate, and epigallocatechin-3,4-di-O-gallate) that displayed more effective binding with the enzyme RdRp than antiviral drugs remdesivir and favipiravir (Bhardwaj, Singh, Sharma, et al., 2021b) . Figure 1 represents the schematic procedure of the present study. SARS-CoV-2 will still be contracted in communities as we face the subsequent influenza epidemic (Singer, 2020) .

According to , nearly 20% of patients infected with SARS-CoV-2 were concurrently infected with at least one other respiratory pathogen, most notably the influenza virus.

There are critical diagnostic implications to this issue. In patients with respiratory symptoms, detecting any respiratory pathogen other than SARS-CoV-2 might not be a valid alternative to rule out COVID-19 infection, especially in areas with limited laboratory resources for SARS-CoV-2 detection in the first place. These findings imply the urgent need for on-demand access to diagnostic tools to detect SARS-CoV-2 and other respiratory pathogens (Singer, 2020) . Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; Cr, creatinine;

CRP, C-reactive protein; CT, computed tomography; DM, diabetes mellitus; Flu, influenza; GGO, ground-glass opacities; GGT, g-glutamyltransferase; Hb, Hemoglobin; ICU, intensive care unit; IV, intravenous; LDH, lactate dehydrogenase; max temp, maximum temperature; NA, nucleic acid; P, patient; PCR, polymerase chain reaction; PR, pulse rate; RR, respiratory rate; T2D, type 2 diabetes; T2DM, type 2 diabetes mellitus. (Fong et al., 2020) . Accordingly, should the transmission rate of COVID-19 spike in the fall of this year, the corresponding preventive measures are most likely to taper the spread of the influenza virus (Singer, 2020) . In terms of higher-level prevention, influenza is thought to be adequately amenable to antiviral therapy in the majority of patients (Dunning et al., 2020) . SARS-CoV-2, on the contrary, is still being investigated for target pathways in its pathogenesis that might render the virus vulnerable to antiviral agents (S. Lu, 2020) . In the case of influenza, vaccine efficacy is a determining factor that depends on the inclusion of the most recently extracted antigens in the vaccine.

The effectiveness of the 2019-2020 influenza vaccine was reported to be 45% in the United States, which is not ideal considering that the vaccine contained the circulating influenza antigen in that year (Dawood et al., 2020 

Mathematical models have long been of particular value for understanding the mechanisms and dynamics of infections. One of the first iterations of such models was developed by Perelson et al. in 1996 to explore the dynamics of human immunodeficiency virus (HIV)

infection (Perelson et al., 1996) , which was later adapted by Nowak et al. and Neumann et al. to investigate hepatitis B (HBV) (Nowak et al., 1996) and hepatitis C viruses (HCV) (Neumann et al., 1998) .

Later, HCV was further investigated by Wodarz et al. (in 2003) in terms of adaptive immunity (Wodarz, 2003) . In 2015, Hattaf and colleagues adapted these models to study HIV, Ebola, and Zika viruses (Hattaf & Yousfi, 2016; Hattaf et al., 2015) . It is recommended that several conditions, known as delays, be considered in the study of infectious diseases. Infection of the host cell and virus

replication are two such delays that occur instantaneously. Equations developed to address these delays are termed delay differential equations (Hattaf & Yousfi, 2020) . Such equations were used by Zhuo 2.5 | Can mathematical models be of help in estimating viral coinfection amid the COVID-19 pandemic?

Mathematical models have had an essential role in extending our understanding of the dynamics of viral respiratory infections (Baccam et al., 2006) . They have also been of particular interest to scientists studying coinfections (Pinky & Dobrovolny, 2020 (Pinky & Dobrovolny, 2020) . Importantly, it has been suggested that the angiotensin-converting enzyme 2 (ACE2) plays a fundamental role in SARS-CoV-2 replication . It is possible that several other strains may target this molecule, and thus, result in suppression of SARS-CoV-2. The influenza virus, for instance, has 

The authors declare no conflicts of interest.

All data are available. 

Safety and immunogenicity of SARS-CoV

SARS-CoV-2 showed a significantly slower growth rate than that of other strains. It was reported that other virus strains readily suppress the SARS-CoV-2 replication. It is possible that several strains, as well as the influenza virus, may target ACE2 molecules, and thus, result in suppression of SARS-CoV-2 by downregulating ACE2. Because it has been suggested that the ACE2 plays a fundamental role in SARS-CoV-2 replication. mRNA-1273 vaccine in older adults

Pharmacy Emergency Preparedness and Response (PEPR): A proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Research in social and administrative pharmacy

Co-infection with SARS-CoV-2 and influenza A virus

Neurological injuries in COVID-19 patients: Direct viral invasion or a bystander injury after infection of epithelial/endothelial cells

Kinetics of influenza A virus infection in humans

COVID-19, modern pandemic: A systematic review from front-line health care providers' perspective

Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs

Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors

Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

-19 influenza season

Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

SARS-CoV-2 and influenza virus co-infection

Dynavax and Clover Biopharmaceuticals announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with CpG 1018 adjuvant, DT Corporation

Interim estimates of 2019-20 seasonal influenza vaccine effectiveness-United States

100 years of influenza research seen through the lens of Covid-19

The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan

Seasonal and pandemic influenza: 100 years of progress, still much to learn

Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings-social distancing measures

Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform

Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients

Dynamics of a generalized viral infection model with adaptive immune response

A class of delayed viral infection models with general incidence rate and adaptive immune response

Mathematical modeling in virology

Association of polymorphisms in tumor necrosis factors with SARS-CoV-2 infection and mortality rate: A case-control study and in silico analyses

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Communityacquired pneumonia requiring hospitalization among U.S. adults

Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine

Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2

Co-infection of coronavirus disease 2019 and influenza: A report from Iran

Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of co-infection

Rates of coinfection between SARS-CoV-2 and other respiratory pathogens

Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus

Co-infection with Influenza A and COVID-19

Co-infections in people with COVID-19: A systematic review and meta-analysis

Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus

A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

Timely development of vaccines against SARS-CoV-2. Emerging microbes infections

Dynamics of a stochastic viral infection model with immune response

COVID-19 to omicron-An overview

Combination attenuation offers strategy for live attenuated coronavirus vaccines

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy

Viral dynamics in hepatitis B virus infection

Co-infection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus/enterovirus?

HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time

Coinfections of the respiratory tract: Viral competition for resources

SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial

Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach

Dynamics of capital-labour model with Hattaf-Yousfi functional response

An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2

COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease

Convalescent blood: Current perspective on the efficacy of a legacy approach in COVID-19 treatment

Application of nanobiotechnology for early diagnosis of SARS-CoV-2 infection in the COVID-19 pandemic

Estimating the burden of

COVID-19 and the next influenza season

COVID-19 and influenza co-infection: Report of three cases

Insilico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors

A computational approach for rational discovery of inhibitors for non-structural protein 1 of SARS-CoV-2

Potential of turmericderived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach

Identification of potential plant bioactive as SARS-CoV-2 spike protein and human ACE2 fusion inhibitors

On facing the SARS-CoV-2 (COVID-19) with combination of nanomaterials and medicine: Possible strategies and first challenges

A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses

Artificial molecular clamp: A novel device for synthetic polymerases

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Is co-infection with influenza virus a protective factor of COVID-19?

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Co-infection of SARS CoV-2 and influenza A in a pediatric patient in Germany

Hepatitis C virus dynamics and pathology: The role of CTL and antibody responses

Positive effects of COVID-19 control measures on influenza prevention

Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia

Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults

Precautions are needed for COVID-19 patients with coinfection of common respiratory pathogens

Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine

Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: Molecular docking, molecular dynamics, and SAR studies

Progress and prospects on vaccine development against SARS-CoV-2. Vaccines

Co-infection with respiratory pathogens among COVID-2019 cases

Analysis of a HBV infection model with non-cytolytic cure process

SARS-CoV-2 and influenza viruses: Strategies to cope with coinfection and bioinformatics perspective